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PGC-1alpha regulates the neuromuscular junction program and
ameliorates Duchenne muscular dystrophy
Abstract
The coactivator PGC-1alpha mediates key responses of skeletal muscle to motor nerve activity. We
show here that neuregulin-stimulated phosphorylation of PGC-1alpha and GA-binding protein (GABP)
allows recruitment of PGC-1alpha to the GABP complex and enhances transcription of a broad
neuromuscular junction gene program. Since a subset of genes controlled by PGC-1alpha and GABP is
dysregulated in Duchenne muscular dystrophy (DMD), we examined the effects of transgenic
PGC-1alpha in muscle of mdx mice. These animals show improvement in parameters characteristic of
DMD, including muscle histology, running performance, and plasma creatine kinase levels. Thus,
control of PGC-1alpha levels in skeletal muscle could represent a novel avenue to prevent or treat
DMD.
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Abstract 
 
The coactivator PGC-1α mediates key responses of skeletal muscle to motor nerve 
activity. We show here that neuregulin-stimulated phosphorylation of PGC-1α and 
GA-binding protein (GABP) allows recruitment of PGC-1α to the GABP complex 
and enhances transcription of a broad neuromuscular junction gene program. 
Since a subset of genes controlled by PGC-1α and GABP is dysregulated in 
Duchenne muscular dystrophy (DMD), we examined the effects of transgenic 
PGC-1α  in muscle of mdx mice. These animals show improvement in parameters 
characteristic of DMD, including muscle histology, running performance and 
plasma creatine kinase levels. Thus, control of PGC-1α levels in skeletal muscle 
could represent a novel avenue to prevent or treat DMD. 
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Introduction 
 
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a 
transcriptional coactivator of nuclear receptors and other transcription factors that 
regulates adaptive mitochondrial function in several other tissues including heart, 
brain, liver and skeletal muscle (reviewed in (Handschin and Spiegelman 2006)). In 
addition to the induction of mitochondrial biogenesis per se, PGC-1α often controls 
biological programs linked to the more oxidative state for a particular tissue. The 
PGC-1 coactivators appear to play a particularly important role in the biology of 
skeletal muscle. PGC-1α induces mitochondrial biogenesis when expressed in 
cultured muscle cells (Wu et al. 1999) and PGC-1α is expressed at highest levels 
in muscle beds rich in the oxidative type I and IIa muscle fibers, such as soleus 
(Lin et al. 2002b). Furthermore, PGC-1α expression is induced in most muscle 
beds by exercise, both chronic and acute, in rodents and humans (e.g. (Russell et 
al. 2003)). PGC-1α is a key mediator of the effects of motor nerve on skeletal 
muscle, suggesting the possibility that it might mediate the anti-atrophic effects that 
nerve activity has on muscle mass. Denervation and/or disuse cause severe 
atrophy of skeletal muscle in both humans and rodents (Kandarian and Jackman 
2006). When PGC-1α levels are maintained transgenically, denervation causes 
much less muscle mass loss and maintains muscle fiber volume (Sandri et al. 
2006). 
 
 - 4 - 
The size and morphology of neuromuscular junctions (NMJ) are key regulators of 
many facets of skeletal muscle function. Genes encoding proteins involved in NMJ 
formation are thought to be controlled, at least in part, by the transcription factor 
GA-binding protein (GABP, alternatively called nuclear respiratory factor 2, NRF-2) 
(Kummer et al. 2006). Transcriptionally active GABP is a heterotetramer of the 
DNA-binding subunit GABPA and the transactivating subunit GABPB. PGC-1α has 
been shown to increase the transcript levels of GABPA and the transcriptional 
activity of GABP, though this original work was done in the context of mitochondrial 
gene expression (Mootha et al. 2004). Two lines of evidence suggested that PGC-
1α might be a strong regulator of the NMJ program in a broad sense. First, PGC-
1α is known to activate mitochondrial biogenesis and muscle fiber-type switching 
(Lin et al. 2002b), both regulated physiologically by exercise and motor-nerve 
activity, as is NMJ remodeling (Wilson and Deschenes 2005). Secondly, PGC-1α 
has been shown to increase GABP activity in transient transfections of the utrophin 
promoter in cultured muscle cells and in muscle in vivo (Angus et al. 2005). 
Whether this is through elevation of GABPA expression by PGC-1α or via physical 
binding and coactivation was not demonstrated. These data raise several key 
questions. First, is PGC-1α a dominant regulator of the broad program of NMJ 
formation in chronic gain and loss of function experiments in vivo? Second, does 
PGC-1α actually bind to and coactivate GABP on the NMJ genes? Finally, how can 
the PGC-1α/GABP complex be responsible for initiating both the mitochondrial 
biogenesis and NMJ gene programs in muscle fibers, when these programs are 
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not linked in synaptic and non-synaptic nuclei in many physiological circumstances 
(Ruegg 2005). 
 
Duchenne muscular dystrophy (DMD) arises from a frame-shift mutation in the X-
linked gene dystrophin and leads to rapid degeneration of heart and skeletal 
muscle, causing disability and death by adolescence or young adulthood 
(Bogdanovich et al. 2004). No therapy described to date can effectively slow or halt 
muscle degeneration in these patients (Kapsa et al. 2003). Interestingly, several 
gene programs that are linked to PGC-1α expression and function are 
dysregulated in DMD. These include reduced capacity for mitochondrial oxidative 
phosphorylation (Kuznetsov et al. 1998; Timmons et al. 2005) and radical oxygen 
species (ROS) detoxification (Disatnik et al. 1998), abnormalities in calcium 
signaling (Chakkalakal et al. 2006) and irregularities in NMJ morphology in muscle 
damage and regeneration (Lyons and Slater 1991). 
 
In the current study, we show that PGC-1α stimulates a broad and powerful 
program of NMJ-linked gene expression both in myotubes in culture and in vivo. 
Moreover, PGC-1α levels correlate with the number of acetylcholine receptor 
clusters in myotubes and isolated single muscle fibers from transgenic animals. We 
show unambiguously that moderately elevated levels of PGC-1α in vivo ameliorate 
a murine model of Duchenne muscular dystrophy (mdx) at the biochemical, 
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histological and functional levels. These data support a new therapeutic approach 
to the muscular dystrophies through PGC-1α. 
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Results 
 
PGC-1α regulates NMJ gene transcription in vitro and in vivo 
 
To investigate if PGC-1α can drive expression of a broad NMJ gene program, we 
assessed the ability of adenoviral-expressed PGC-1α to induce expression of NMJ 
genes in C2C12 myotubes. After infection for 48 hours with adenoviral vectors 
encoding PGC-1α, elevation of mRNA encoding acetylcholine receptor ε (AChRε), 
AChEst, utrophin, ErbB2, laminin β2 (laminin), rapsyn and GABPA mRNA levels 
were observed (Fig. 1A). The expression of these genes, all of which are related to 
NMJ formation and function, is increased in the range of 3 to 8 fold compared to 
control cells infected with a GFP-expressing adenovirus. 
 
The muscle-specific PGC-1α transgenic mouse represents a model of chronically 
elevated PGC-1α expression (Lin et al. 2002b). Importantly, this mouse model has 
moderate elevation of PGC-1α in most muscle beds, to the level of this protein 
observed in muscle beds rich in oxidative fibers, such as soleus. In gastrocnemius 
of these animals, increased transcript levels of AChRα, AChRδ, AChRε, AChEst, 
utrophin, ErbB2, rapsyn and GABPA are observed compared to wild-type skeletal 
muscle (Fig. 1B). 
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PGC-1α whole body knockout mice have a complex phenotype characterized by 
massive lesions in the brain and behavioral abnormalities (Lin et al. 2004; Leone et 
al. 2005; St-Pierre et al. 2006). In particular, these mice are hyperactive and show 
Huntington-like behavior. Unfortunately, many of the phenotypes resulting from 
ablation of PGC-1α in peripheral tissues in these mice are thus confounded by the 
hyperactivity. The validity of tissue-specific knockout of PGC-1α has been proven 
in liver-specific PGC-1α knockout mice, which have clear and expected changes in 
liver function (Handschin et al. 2005). Accordingly, to selectively study the 
postsynaptic side of NMJs in skeletal muscle and to avoid the confounding effects 
of genetic ablation of PGC-1α in the central nervous system, we generated a 
skeletal muscle-specific PGC-1α knockout animal by crossing mice with a floxed 
PGC-1α allele with animals that transgenically express cre recombinase under the 
control of the myogenin promoter and MEF2C enhancer. Similar to total knockouts, 
mitochondrial gene expression and exercise capacity is reduced in these mice 
(data not shown). Importantly, muscle-specific knockout mice have reduced 
expression of myosin heavy chains I and IIa and show no signs of hyperactivity, in 
contrast to whole body PGC-1α knockout animals (data not shown). In 
gastrocnemius, AChRα, AChRδ, AChRε, utrophin, ErbB2, Musk and GABPA 
expression levels are reduced between 30 to 70% in the muscle-specific knockout 
of PGC-1α as compared to control animals (Fig. 1C). Thus, PGC-1α is required for 
normal expression of the NMJ gene program. Together, elevation and ablation of 
PGC-1α expression in skeletal muscle in vivo both have marked effects on the 
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transcription of NMJ genes. NMJ genes are regulated slightly differently in this 
experimental in vitro system and in vivo. Importantly, the program of NMJ genes is 
consistently regulated in C2C12 cells, MCK-PGC-1α and MKO mice (7 out of 10 
genes studied in C2C12, 8 out of 10 genes in MCK-PGC-1α and 8 out of 10 genes 
in MKOs). 
 
PGC-1α increases AChR clusters in myotubes 
 
We next studied the effect of PGC-1α on acetylcholine receptor (AChR) clustering 
in C2C12 myotubes induced by overnight treatment with 10 ng/ml of a recombinant, 
C-terminal fragment of rat agrin. C2C12 myoblasts and myotubes have very low 
levels of endogenous PGC-1α. Untreated, GFP-infected myotubes show only 
sporadic clustering of AChR on the cell membrane (Fig. 2A, panel 1). Agrin 
treatment of GFP-infected myotubes greatly increases the number of AChR 
clusters (Fig. 2A, panel 2). Surprisingly, forced expression of PGC-1α using 
adenoviral vectors results in a marked increase in AChR clusters, even in the 
absence of agrin (Fig. 2A, panel 3). Upon treatment with agrin, a further increase in 
AChR clusters was observed in PGC-1α-infected C2C12 myotubes (Fig. 2A, panel 
4). In vehicle-treated myotubes, the clusters appear more dispersed as compared 
to the clusters on agrin-treated cells. This might be due to the PGC-1α-mediated 
increase in AChRs at the cell membrane, which are able to bind α-bungarotoxin. 
Adenoviral-encoded PGC-1α does not change endogenous agrin transcript levels 
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in C2C12 cells (Supplemental Fig. S1). Importantly, these dispersed AChR clusters 
are focused by treatment with exogenous agrin. These results demonstrate that 
PGC-1α promotes an increase of AChR clusters on the cell membrane (see 
Supplemental Fig. S2 for quantification). 
 
To investigate if AChR cluster numbers are affected by the relative levels of PGC-
1α in muscle fibers of gain- and loss-of-function animals, we isolated single muscle 
fibers from control, MCK-PGC-1α muscle-specific transgenic mice and muscle-
specific PGC-1α knockout animals. AChR clusters were stained with fluorescent α-
bungarotoxin (α-BTX) and their relative number normalized by the muscle fiber 
area as assessed by the numbers of nuclei stained with DAPI (4',6-diamidino-2-
phenylindole). Twenty different randomly chosen fields per animal were analyzed 
in blinded fashion and the average reported. Single muscle fibers from MCK-PGC-
1α had a higher number of AChR clusters per muscle fiber area than control 
animals (Fig. 2B). In contrast, fewer AChR clusters were counted in PGC-1α 
muscle-specific knockout animals in comparison to control littermates (Fig. 2C). 
The increase in AChR clusters in the fibers of PGC-1α muscle-specific transgenic 
mice and the decrease in the fibers of muscle-specific PGC-1α knockout animals 
were both significant, with an increase of 85% in MCK-PGC-1α fibers and a 
decrease of 19% in MKO fibers (Fig. 2B, C). Representative images and additional 
quantification are shown in Supplemental Fig. S3. Thus, PGC-1α drives the 
formation of AChR clusters when expressed ectopically in immortalized cell lines 
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that are differentiated into myotubes. Moreover, the number of aneural 
acetylcholine receptor clusters in isolated single muscle fibers from MCK-PGC-1α 
and MKO animals correlate with the relative expression levels of PGC-1α. 
 
PGC-1α binding to and coactivation of GABP depends on specific protein 
phosphorylation events 
 
PGC-1α in skeletal muscle has been shown to induce GABPA mRNA levels and 
increase GABP activity in the context of transcriptional regulation of mitochondrial 
genes, but direct binding and coactivation was not determined (Mootha et al. 2004). 
Similarly, PGC-1α and GABP increase reporter gene expression driven by the 
utrophin promoter construct, although again, direct binding of PGC-1α to GABP 
could not be shown (Angus et al. 2005). GABP represents a likely candidate 
transcription factor recruiting PGC-1α to NMJ promoters, but whether and how 
these events occur is unclear. In reporter gene assays using promoter fragments 
from AChRδ, AChRε and utrophin, PGC-1α stimulated GABP-mediated 
transcription of all three promoters (Fig. 3A). Transcriptional activity of GABP, 
PGC-1α and the combination of these two proteins is completely dependent on the 
integrity of the N-box present in all three promoters (Fig. 3A). These results show 
that PGC-1α induces transcription of these NMJ genes via the N-box, the DNA-
binding site for GABP. In skeletal muscle, signaling cascades initiated by trophic 
factors such as agrin or neuregulin-1 (NRG-1) result in phosphorylation of GABP 
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(Bezakova and Ruegg 2003; Sunesen and Changeux 2003). Interestingly, 
mitogen-activated protein kinase (MAPK) has been found to phosphorylate both 
GABP (Flory et al. 1996) as well as PGC-1α (Puigserver et al. 2001). These 
phosphorylation events are critical in boosting the transcriptional activity of GABP 
(Sunesen et al. 2003). We therefore mutated the known p38 MAPK 
phosphorylation-sites on GABPA (threonine 280) and GABPB1 (serine 170 and 
threonine 180) (Fromm and Burden 2001) and used these phosphorylation-
mutants along with the PGC-1α allele with mutated MAPK-phosphorylation sites 
(PGC-1α 3A, threonine 262, serine 265 and threonine 298) (Puigserver et al. 2001) 
in reporter gene assays with the AChRδ, AChRε and utrophin promoters. Mutation 
of the three phosphorylation sites on PGC-1α resulted in complete ablation of 
PGC-1α-mediated co-activation of GABP on all three promoters (Fig. 3B). Similarly, 
preventing the phosphorylation of GABPA and GABPB1 abolished transcriptional 
induction of the AChRδ, AChRε and utrophin promoters by GABP and PGC-1α (Fig. 
3B). Using the phosphorylation mutants for GABPA and GABPB1 individually 
resulted in a partially reduced transcriptional activity of the GABP/PGC-1α complex 
(Supplementary Fig. S4). These data underline the previously reported importance 
of the phosphorylation events on GABP (Sunesen et al. 2003) and furthermore 
show that phosphorylation of PGC-1α is equally crucial for promoting expression of 
these NMJ genes. 
 
NRG-1 action requires phosphorylation of PGC-1α and GABP 
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NRG-1 promotes phosphorylation of GABP in skeletal muscle and induces the 
expression of NMJ genes (Kummer et al. 2006). In reporter gene assays using the 
AChRδ, AChRε and utrophin promoters, NRG-1 dramatically increases the ability 
of GABP and PGC-1α to promote reporter gene expression (Fig. 3C). Finally, the 
NRG-1-mediated boost in activation of these three promoters by PGC-1α/GABP is 
markedly reduced when using dominant-negative GABP. Dominant-negative 
GABPA lacking the C-terminal dimerization domain and dominant-negative 
GABPB1 lacking the C-terminal transcriptional activation signal and the 
homodimerization domain have been described (see (Sunesen et al. 2003) and 
references therein). We used those in combination with the GABP and PGC-1α 
phosphorylation mutants to test the ability of these mutants to block NRG-1 activity 
on the NMJ promoters. We found that functional PGC-1α and GABP are essential 
for proper regulation of reporter gene transcription (Fig. 3D). Induction of 
endogenous NMJ genes by transfected PGC-1α in C2C12 cells is significantly 
blunted by addition of expression vectors for dominant negative GABP 
(Supplemental Fig. S5). Together, these experiments show that PGC-1α and 
GABP functionally interact and drive the expression of several NMJ genes. 
Moreover, activation of the AChRδ, AChRε and utrophin promoters by NRG-1 
requires phosphorylation of both GABP and PGC-1α. 
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To date, no direct protein interaction between GABP and PGC-1α has been 
demonstrated (our unpublished observations and (Scarpulla 2002; Baar 2004; 
Angus et al. 2005)). However, our results highlighting the importance of the 
phosphorylation of both GABP and PGC-1α for NMJ gene expression suggested 
that these posttranslational modifications could be important for stabilizing their 
physical interaction as well. Moreover, host cell factor (HCF) was found to bind to 
both GABPB (Vogel and Kristie 2000) and to PGC-1α (Lin et al. 2002a) and thus 
could potentially serve as a linker between GABP and PGC-1α. The importance of 
the phosphorylation and binding of HCF in the formation of a GABP-PGC-1α 
complex were tested in co-immunoprecipitation assays in BOSC cells. Myc-tagged 
GABPA, myc-tagged GABPB1 and flag-tagged PGC-1α were co-transfected, cell 
extracts were immunoprecipitated with anti-myc antibody and subsequently blotted 
with anti-myc and anti-flag antibodies. In this context, flag-tagged PGC-1α was not 
associated with myc-tagged GABP (Fig. 4A, lane 2). Next, phosphorylation of 
PGC-1α, GABPA and GABPB1 was induced by co-transfection of constitutively 
active mitogen-activated protein kinase kinase kinase (MEKK*). Transfection of 
MEKK* resulted in increased PGC-1α protein levels as published (Fig. 4A, lanes 3 
and 5) (Puigserver et al. 2001). No physical interaction between PGC-1α and 
GABP was observed with co-transfected MEKK* (Fig. 4A, lane 3). Similarly, 
addition of HCF expression plasmid yielded no co-immunoprecipitation of PGC-1α 
with GABP (Fig. 4A, lane 4). However, co-transfection of both constitutively active 
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MEKK* and HCF strongly promoted a physical interaction as evidenced by 
detection of flag-PGC-1α after anti-myc immunoprecipitation (Fig. 4A, lane 5). 
 
Having established the importance of phosphorylation and presence of HCF for 
physical interaction between PGC-1α and GABP, we further tested if 
phosphorylation of GABPA, GABPB1 or PGC-1α is important for the interaction. 
Substitution of wild-type PGC-1α with the PGC-1α 3A allele completely abolished 
the interaction between PGC-1α and GABP (Fig. 4B, lanes 2 vs. 3). Similarly, 
mutation of the phosphorylation sites of GABPB1 resulted in greatly diminished co-
immunoprecipitation of PGC-1α and GABP (Fig. 4B, lane 4). In contrast, 
phosphorylation of GABPA is not important for this interaction (Fig. 4B, lane 5). As 
predicted, co-transfection of phosphorylation-mutants for GABPA, GABPB1 and 
PGC-1α did not result in any interaction (Fig. 4B, lane 6). In all of these 
experiments, we used constitutively active MEKK* to induce phosphorylation of 
GABP and PGC-1α. To see if the interaction between PGC-1α and GABP can be 
recapitulated in a more physiological context, co-immunoprecipitation experiments 
were performed in C2C12 myotubes treated with NRG-1. Interestingly, NRG-1 
promoted co-immunoprecipitation of PGC-1α with GABP even in the absence of 
exogenous HCF (Fig. 4C, lane 3 with NRG-1 vs. lane 1 without NRG-1 treatment). 
However, addition of HCF further stimulated the interaction (Fig. 4C, lane 4). Our 
data demonstrate that PGC-1α and GABP are found in a complex following 
phosphorylation of both PGC-1α and GABPB1 and that HCF is an important part of 
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the protein complex (Fig. 4D). Phosphorylation of the GABPA subunit has been 
reported to be absolutely indispensable for transcriptional activity and changes in 
intra-nuclear mobility of the GABP complex (Sunesen et al. 2003). In contrast, the 
function of the GABPB phosphorylation remained unclear (Sunesen et al. 2003). 
Our findings suggest that GABPB1 phosphorylation is needed for the recruitment 
of PGC-1α, perhaps via the interaction with HCF that exclusively binds to GABPB 
and not GABPA (Vogel and Kristie 2000). The phosphorylation of PGC-1α and 
GABP could furthermore control the specificity of the coactivation and direct the 
protein complex to NMJ gene promoters. Thus, in primary myotubes derived from 
wild-type animals, NRG-1 significantly induced expression of AChRδ, AChRε, 
AChEst, utrophin and Musk (Fig. 5A). In marked contrast, this induction was 
completely lost in PGC-1α knockout myotubes. In contrast to NMJ genes, none of 
the PGC-1α target genes involved in metabolic pathways is regulated by NRG-1 in 
wild-type and PGC-1α knockout primary myotubes, respectively (Fig. 5B). These 
genes have previously been shown to be under transcriptional control of GABP 
and ERRα coactivated by PGC-1α (Mootha et al. 2004). Finally, the 
phosphorylation-deficient PGC-1α 3A protein has no transcriptional activity on NMJ 
promoters and this protein is unable to interact with GABP in this context (Fig. 5C). 
Surprisingly, PGC-1α 3A is as efficient in increasing GABP activity on the ERRα 
promoter as wild-type PGC-1α (Fig. 5C). Wild-type PGC-1α and PGC-1α 3A both 
coactivate ERRα on the ERRα promoter to the same extent (Fig. 5D). In addition, 
wild-type PGC-1α and the PGC-1α 3A protein were also equally potent in 
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coactivating the nuclear respiratory factor 1 in reporter gene assays 
(Supplementary Fig. S6). These results clearly show that increase of mitochondrial 
genes by coactivation of GABP by PGC-1α is different from the induction of NMJ 
genes in that it requires phosphorylation of PGC-1α and GABP. Moreover, 
phosphorylation stimulated by NRG-1 only elevates NMJ genes, but not 
mitochondrial or other PGC-1α target genes in skeletal muscle cells. Thus, NRG-1 
directs modifications of GABP and PGC-1α and induces a very specific subset of 
GABP/PGC-1α target genes in skeletal muscle fibers. 
 
PGC-1α ameliorates muscular dystrophy in sedentary DMD (mdx) mice 
 
Many genes controlled by PGC-1α are dysregulated in DMD (see Discussion 
section for an overview). We therefore examined the effect of transgenic 
expression of PGC-1α on the disease phenotype of mdx mice by interbreeding with 
MCK-PGC-1α muscle-specific transgenic animals. The main pathology in mdx 
mice is detected at the age of 4-6 weeks. We thus analyzed our animals at 5 
weeks of age. Introducing the PGC-1α transgene into the mdx background 
reduced serum creatine kinase levels by about 55% (Fig. 6A). As compared to 
control and MCK-PGC-1α transgenic mice, haematoxylin and eosin (H&E) staining 
of crossections of mdx gastrocnemius muscles show a large proportion of muscle 
fibers with centrally located nuclei (Fig. 6B). Muscle fibers with centrally located 
nuclei are a hallmark of regenerating muscle and their relative number is 
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proportional to muscle damage in mdx mice (e.g. reviewed in (Briguet et al. 2004)). 
In MCK-PGC-1α/mdx mice, the relative numbers of muscle fibers with centrally 
located nuclei are reduced by 44% as compared to mdx animals (Fig. 6B, 
Supplemental Fig. S7). Intraperitoneal injection of Evans blue is commonly used to 
assess skeletal muscle fiber lesions, since this dye will only penetrate damaged 
fibers. As expected, no damaged fibers were found in gastrocnemius of control or 
MCK-PGC-1α transgenic mice (Fig. 6C). A substantial proportion of muscle fibers 
in mdx mice is damaged as indicated by penetration of Evans blue (Fig. 6C). In 
contrast, expression of the PGC-1α transgene in skeletal muscle of mdx mice 
reduces the fraction of damaged muscles by about 55% (Fig. 6C, Supplemental 
Fig. S6). These results clearly demonstrate that elevation of PGC-1α levels in 
skeletal muscle has a beneficial effect on the muscular dystrophy in mdx mice 
through a reduction in muscle fiber damage. It is conceivable that this improvement 
is at least in part mediated by increased utrophin levels in MCK-PGC-1α/mdx mice 
compared to mdx animals (Supplemental Fig. S8). 
 
PGC-1α improves muscular dystrophy in physically challenged mdx mice 
 
In contrast to human DMD patients, mdx mice have a relatively mild muscular 
dystrophy that is most noticeable at the age of 4-6 weeks and is later offset by 
compensatory upregulation of utrophin and massive muscle regeneration (Bulfield 
et al. 1984). Dystrophin provides mechanical reinforcement to the sarcolemma and 
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its absence increases the susceptibility of muscle fibers to contractile stress. 
However, mdx mice challenged with eccentric physical exercise constitute a more 
reliable model of the human disease than sedentary mdx animals (Brussee et al. 
1997). Thus, wild-type, MCK-PGC-1α, mdx and MCK-PGC-1α/mdx were run on a 
treadmill for one hour at 15 degrees downhill. Subsequently, this exercise protocol 
was repeated 24 hours after the first run. Importantly, this exercise protocol is not 
exhaustive for wild-type animals. Accordingly, wild-type and MCK-PGC-1α animals 
had no problems running one hour on two consecutive days (Fig. 7A). In contrast, 
mdx mice barely make it through 50% of each run (Fig. 7A). MCK-PGC-1α/mdx 
animals perform almost as well as control mice in the first run; they showed a 
decreased performance in the second run, though their performance in the second 
run is still significantly better than that of mdx mice in the first or the second run 
(Fig. 7A). 
 
Two hours after the first run, serum creatine kinase activity was determined, which 
are a reflection of the muscle damage induced by the eccentric exercise. Serum 
creatine kinase levels of mdx animals were about 7 fold higher that those in 
sedentary mdx mice (Fig. 7B vs. Fig. 6B). The MCK-PGC-1α/mdx mice had a 50% 
reduction in creatine kinase levels after exercise, similar to the reduction observed 
in sedentary animals (Fig. 7B). Histological analysis of quadriceps muscles from 
mice sacrificed after the second run revealed lower number of necrotic lesions in 
the MCK-PGC-1α/mdx mice as compared to mdx animals (Fig. 7C). Moreover, a 
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greater number of large and non-centrally nucleated fibers are found in MCK-PGC-
1α/mdx than mdx mice (Fig. 7C, Supplemental Fig. S7). Similarly, fiber damage as 
determined by Evans blue uptake is lower in MCK-PGC-1α/mdx diaphragms 
versus mdx diaphragms (Fig. 7D, Supplemental Fig. S7). Thus, the moderately 
elevated PGC-1α in skeletal muscle results in an improvement in fiber damage, 
fiber necrosis and a decrease in serum creatine kinase levels in a mouse model of 
DMD to an extent that results in vastly improved exercise tolerance. Together, 
these effects of ectopic expression of PGC-1α show a clear and substantial 
improvement in the structure and function of skeletal muscle in this disease model. 
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Discussion 
 
The size and morphology of NMJs evolves in development and changes according 
to the relative degree of physical activity and the fiber-type distribution (Wilson and 
Deschenes 2005; Hughes et al. 2006). NMJ formation and plasticity are controlled 
by the trophic factors agrin and NRG-1 released from the motor neuron (Kummer 
et al. 2006). Agrin stimulates clustering of AChRs at the site of the NMJ and 
promotes transcription of NMJ-specific genes. NRG-1 is sufficient to induce 
transcript levels of many NMJ genes, although recent reports showed that NRG-1 
signaling is not required for NMJ formation in vivo (Escher et al. 2005; Jaworski 
and Burden 2006). Importantly, agrin and NRG-1 signaling both converge on the 
transcription factor GABP (Briguet and Ruegg 2000). The two GABP subunits, 
GABPA and GABPB, are subsequently phosphorylated and bind to N-box 
elements in the promoters of NMJ genes. We now show that PGC-1α is a powerful 
transcriptional regulator of the NMJ gene program, at least in part by a bona fide 
coactivation of GABP. Moreover, we demonstrate that the relative levels of PGC-
1α are important for the formation of acetylcholine receptor clusters in isolated 
muscle fibers. The changes in NMJ gene expression and in relative AChR cluster 
numbers induced by PGC-1α in the basal (non-exercised) state are moderate. 
Moreover, NMJ formation per se can clearly happen in vivo in the absence of PGC-
1α. As observed for PGC-1α in skeletal muscle in general, this coactivator does 
not regulate basal functions as much as adaptive changes in response to exercise 
 - 22 - 
and other physiological alterations. The rapid changes in PGC-1α levels upon 
physical exercise and inactivity (e.g. (Pilegaard et al. 2003; Russell et al. 2003)) 
imply that PGC-1α is probably very important for adaptive changes in the NMJ 
gene program in certain contexts. In addition, as shown here, the changes induced 
by PGC-1α are striking in mice with an mdx background. 
 
Induction of GABPA transcript levels and increase of GABP activity by PGC-1α in 
the context of mitochondrial genes has previously been shown (Mootha et al. 2004). 
However, we here show for the first time that PGC-1α physically interacts with and 
coactivates GABP. Importantly, our results give an indication as to how PGC-1α 
and GABP specifically regulate NMJ gene expression in synaptic nuclei. PGC-1α is 
required for the effects of NRG-1 that promotes phosphorylation of GABP to 
increase transcription of NMJ genes. Furthermore, we found that the interaction 
between PGC-1α and GABP is highly dependent on the phosphorylation state of 
PGC-1α and GABPB1, the transactivating subunit of GABP. Phosphorylation of 
GABPA has previously been reported to change the mobility of the GABP complex 
in the nucleus (Sunesen et al. 2003). The significance of the GABPB1 
phosphorylations has not been clear to date (Sunesen et al. 2003). Here, we 
propose that these posttranslational modifications on GABPB1 control the 
recruitment of PGC-1α to GABP. In addition, PGC-1α requires the presence of 
HCF in the PGC-1α-GABP protein complex. Additional members of the 
transcriptional PGC-1α/HCF/GABP complex and the exact domains mediating this 
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interactions will be identified in future studies. In all the interactions studied to date, 
PGC-1α directly binds to the transcription factor it coactivates. Why coactivation of 
GABP by PGC-1α requires these additional steps is not clear. However, it is 
plausible that the requirement for phosphorylations and the presence of HCF may 
control the interaction between PGC-1α and GABP specifically in synaptic nuclei 
where NMJ genes are expressed. Unfortunately, due to the lack of suitable tools, 
we were not able to study the significance of the phosphorylation of endogenous 
PGC-1α and GABP. Obviously, characterizing the post-translational modifications 
of the endogenous proteins in skeletal muscle in vivo will contribute to our 
understanding of the signaling cascades involved in NMJ remodeling in the future. 
 
PGC-1α muscle-specific transgenic mice in an mdx background have lower 
creatine kinase levels, reduced necrotic lesions, decreased fiber damage and 
increased muscle function. NRG-1 treatment, which improves the function of mdx 
mice (Krag et al. 2004) has been proposed to work through upregulation of 
utrophin since NRG-1 has no beneficial effect in dystrophin/utrophin double-
knockout animals (Krag et al. 2004) and transgenic expression of utrophin 
ameliorates muscle damage in mdx animals (Tinsley et al. 1998). One obvious link 
between the PGC-1α-mediated changes in NMJ gene expression and amelioration 
of muscle dystrophy in mdx mice is the induction of utrophin mRNA and protein 
(Fig. 1 and Supplemental Fig. S9). Elevation of utrophin has been proposed to 
constitute a therapeutic approach to Duchenne muscular dystrophy (Miura and 
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Jasmin 2006). However, although the outcome of crossing muscle-specific PGC-
1α transgenic animals into a dystrophin/utrophin double-knockout background is 
unknown, there is strong evidence suggesting that PGC-1α has beneficial effects 
on Duchenne muscular dystrophy that go well beyond simple increase of utrophin 
expression. First, PGC-1α has an anti-atrophic effect on muscle fibers in sciatic 
nerve denervation (Sandri et al. 2006). The exact mechanism of this effect is 
unknown, but it is clear that PGC-1α inhibits the function of the pro-atrophic 
transcription factor FoxO3 and blunts induction of the atrogenes atrogin-1, MuRF-1 
and cathepsin-L (Sandri et al. 2006). Recent data have shown that dystrophin 
disruption as observed in DMD results in downregulation of Akt signaling, 
subsequent activation of FoxO3 and elevation the atrogenes (Acharyya et al. 2005). 
Second, PGC-1α is a potent regulator of mitochondrial biogenesis and oxidative 
metabolism in skeletal muscle (Wu et al. 1999; Lin et al. 2002b). The skeletal 
muscles of mdx mice have impaired oxidative phosphorylation and mitochondrial 
function (Kuznetsov et al. 1998; Timmons et al. 2005). Moreover, in skeletal 
muscle of DMD patients, a general metabolic crisis is precipitated by a large-scale 
downregulation of nuclear-encoded mitochondrial genes (Chen et al. 2000). Third, 
PGC-1α is direct target of calcium/calmodulin signaling in skeletal muscle (Wu et al. 
2002; Handschin et al. 2003). Disruption of calcium/calmodulin signaling in mdx 
mice exacerbates the dystrophic phenotype (Chakkalakal et al. 2006). Fourth, mdx 
show abnormalities in NMJ morphology in fiber damage and regeneration (Lyons 
and Slater 1991) that might be prevented by the PGC-1α-mediated induction of 
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NMJ genes. Finally, reactive oxygen species (ROS) may be causally linked to the 
muscle damage in DMD (Disatnik et al. 1998). The normal cellular response to 
ROS challenge relies on PGC-1α, which is a potent driver of the gene program for 
ROS defense (St-Pierre et al. 2006). 
 
In summary, PGC-1α most likely improves muscle dystrophy by multiple molecular 
pathways. Thus, an increase in PGC-1α levels or PGC-1α activity and recruitment 
to specific transcription factors such as GABP represent a promising and novel 
strategy for the treatment of DMD, the related Becker muscular dystrophy, and 
other neuromuscular diseases. 
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Materials and methods 
 
Plasmids and reagents 
Promoter constructs for AChRδ (770 bp), AChRε (210 bp) and utrophin (1.2 kb) 
were amplified by PCR and subcloned into the pGL3 basic luciferase reporter gene 
plasmid (Promega) similar to published constructs (Koike et al. 1995; Duclert et al. 
1996; Gramolini et al. 1998). Mutations of the N-box DNA elements in these 
promoters were obtained by PCR-mediated site-directed mutagenesis. 
Phosphorylation mutants of GABPA (threonine 280) and GABPB1 (serine 170 and 
threonine 180) were obtained by site-directed mutagenesis replacing the 
threonines and serines with alanines. Myc-tags were C-terminally attached to 
GABPA and N-terminally to GABPB1 by PCR. Dominant negative GABPA and 
GABPB1 alleles lacking amino acids 400 to 454 and 330 to 383, respectively, were 
obtained by PCR. Constitutively active MEKK3 was used to induce phosphorylation 
of PGC-1α and GABP. All constructs were verified by sequencing. Recombinant 
rat C-terminal agrin and recombinant human NRG-1 extracellular domain were 
purchased from R&D Systems. tetramethylrhodamine-labeled α-bungarotoxin was 
obtained from Invitrogen. 
 
Mdx animals 
C57BL/10ScSn-Dmdmdx/J mice (mdx mice) (Bulfield et al. 1984) were purchased 
from Jackson Laboratories. These mice were crossed with the previously 
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described muscle-specific PGC-1α transgenic animals (Lin et al. 2002b). To control 
variations of different genetic backgrounds (MCK-PGC-1α: C57Bl/6J, mdx: 
C57Bl/10ScSnJ), only littermates from the breeding were used in sufficient number 
per experimental group. Sedentary mice were analyzed at the age of 5 weeks, 8 
animals per group. For the exercise experiment, mice at the age of 12 weeks were 
used, 6 animals per group. 
 
PGC-1α muscle-specific knockout animals 
The generation of mice with a floxed PGC-1α allele has been described (Lin et al. 
2004). To obtain muscle-specific knockout animals, mice with a loxed PGC-1α 
allele were crossed with animals transgenically expressing cre recombinase under 
the control of the myogenin promoter and MEF2C enhancer (a generous gift from 
Rhonda Bassel-Duby and Eric N. Olson) (Li et al. 2005). However, male mice with 
the floxed PGC-1α allele are infertile because of the presence of the neomycin 
cassette. Thus, muscle-specific knockout animals could only be obtained in mice 
with one floxed and one knockout allele of PGC-1α (lox/-, myogenin-cre). As 
control mice, we used a mixed population of different mice heterozygous for PGC-
1α (lox/-; +/-; +/-, myogenin-cre). A detailed description of the muscle-specific 
knockout animals will be published elsewhere. Muscle-specific knockout animals 
and MCK-PGC-1α animals were sacrificed at the age of 6 weeks to analyze gene 
expression and 6 animals per genotype were used. 
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Cell culture 
C2C12 cells were cultured in DMEM (Invitrogen) with 10% FBS (Gibco) and 
differentiated in DMEM with 2% horse serum (Gibco) for 3 days. Differentiated 
myotubes were infected with adenoviral vectors and cells were harvested after 48 
hours. Primary muscle cells were isolated from whole hind leg muscles by 
enzymatic digestion with collagenase/dispase (Roche) and serial plating on 
collagen-coated culture dishes (BD Biosciences). These cells were cultured in 
Ham’s F-10 medium (Invitrogen) supplemented with 20% FBS (Hyclone) and 2.5 
ng/ml basic fibroblast growth factor (Invitrogen). Differentiation was induced by 
addition of DMEM with 5% horse serum. 
 
Single muscle fiber culture and NMJ quantification 
Single muscle fibers were prepared as described (Rosenblatt et al. 1995). Briefly, 
extensor digitorum longus (EDL) muscle was removed from 6-week old animals by 
cutting the tendons. The muscle was placed in 0.2% collagenase solution and 
incubated at 35 degrees for 60 minutes. Single muscle fibers were liberated from 
the EDL by shearing using heat-polished Pasteur pipettes in DMEM supplemented 
with 10% horse serum (Gibco). The fibers were washed in PBS and fixed in 1.5% 
paraformaldehyde for 10 minutes. Subsequently, the fibers were stained with α-
bungarotoxin in PBS for 30 minutes, washed twice in PBS with 20 mM glycine and 
transferred to a glass slide. The fibers were embedded in SlowFade Gold antifade 
reagent with DAPI (Invitrogen) and analyzed by fluorescent microscopy. At a 60x 
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magnification, 20 fields containing muscle fibers were randomly chosen per animal 
and the number of NMJs as well as the number of nuclei counted. For the 
histogram depicting the relative number of AChR clusters per muscle fiber, 50 
muscle fibers per genotype were analyzed and AChR counted. 
 
Transient transfections 
C2C12 myoblasts were transfected with Lipofectamine 2000 at 80% confluency 
and subsequently differentiated for 2 days. In some experiments, cells were treated 
for 2 days with vehicle or 5 nM NRG-1. Then, cells were harvested, luciferase 
activity measured and normalized to β-galactosidase levels. 
 
Co-immunoprecipitation 
BOSC cells were transfected by calcium phosphate precipitation (Promega). Two 
days after transfection, cells were harvested, proteins isolated and 1 mg of protein 
extract used for immunoprecipitation with anti-myc beads (Santa Cruz). Proteins 
were subsequently eluted from the beads and analyzed by Western blotting using 
anti-flag (Sigma) and anti-myc (Santa Cruz) antibodies along with 10 μg of input. 
C2C12 cells were transfected by calcium phosphate precipitation at 80% 
confluency, differentiated for 2 days and simultaneously treated with vehicle or 5 
nM NRG-1. Then, cell were harvested and processed as described above. 
 
Acetylcholine receptor clustering in vitro 
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C2C12 cells were differentiated for 3 days and infected with adenoviral vectors 
encoding GFP and PGC-1α, respectively. After 1.5 days, cells were treated with 
vehicle or 10 ng/ml agrin for 16 hours. Cells were fixed in 3% formaldehyde, 
incubated with α-bungarotoxin to stain NMJs and analyzed by fluorescence 
microscopy. 
 
Histological analysis, Evans blue injection 
Tissues were dissected, embedded in OCT compound (VWR), dehydrated, 
embedded in paraffin and sectioned. The sections were subsequently stained with 
haematoxilin and eosin (H&E). Evans blue dye (1% solution) was i.p. injected at a 
concentration of 1% volume per bodyweight. After 16 hours, mice were sacrificed 
and skeletal muscle frozen histological sections prepared. Evans blue 
incorporation was analyzed by fluorescence microscopy. Evans blue-penetrated 
muscle fibers and fibers with centrally located nuclei were counted in 20 randomly 
chosen sections in blinded fashion and were normalized by the total number of 
muscle fibers per field. 
 
RNA isolation and real-time PCR analysis 
Total RNA from cells or tissues was prepared using the Trizol reagent (Gibco). 
Before reverse transcription, 1 μg of total RNA was treated with DNase I (Roche) 
and then treated with MMLV reverse transcriptase (Invitrogen). This cDNA was 
subsequently analyzed by semiquantitative real-time PCR using the ΔΔCt method 
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on an Applied Biosystems Real-Time PCR System 7300. Relative gene expression 
levels were normalized to 18S rRNA expression. 
 
Serum creatine kinase assay 
Mouse blood was collected and serum isolated using heparin-coated collection 
tubes (BD Biosciences). Serum creatine kinase activity was then determined with 
the Creatine Kinase-SL Assay Kit according to the manufacturers protocol 
(Diagnostic Chemicals Limited). 
 
Treadmill exercise 
Animals ran on a treadmill tilted 15 degrees downhill until exhaustion or for 
maximal 60 minutes. The running protocol consisted of 5 minutes at 10 m/min, 5 
minutes at 15 m/min, 5 minutes at 20 m/min and 45 minutes at 25 m/min. The run 
was repeated 24 hours after the first run. 
 
Western blotting 
Protein extract from gastrocnemius (100 μg) were run on a 6% polyacrylamide gel, 
transferred to PVDF membrane and blotted for utrophin using an anti-utrophin 
antibody (Santa Cruz). 
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Figure Legends 
 
Fig. 1. PGC-1α regulates NMJ gene expression. A, C2C12 myotubes were 
infected with adenoviral vectors encoding GFP and PGC-1α, respectively, on day 3 
after differentiation. RNA was harvested 48 hours later and relative gene 
expression levels measured by real-time PCR. *p<0.05 between GFP- and PGC-
1α-infected cells. B, Gastrocnemius muscle was isolated from wild-type and PGC-
1α muscle-specific transgenic animals (MCK-PGC-1α). After RNA isolation, 
relative gene expression was analyzed by real-time PCR. *p<0.05 between control 
and transgenic animals. C, Control and PGC-1α muscle-specific knockout animals 
(PGC-1α MKO) were sacrificed, RNA isolated from gastrocnemius and relative 
gene expression levels measured by real-time PCR. *p<0.05 between control and 
muscle-specific knockout animals. The bars depict average gene expression 
normalized to 18S rRNA levels with the error bars representing standard deviations.  
 
Fig. 2. Acetylcholine receptor clustering induced by PGC-1α. A, C2C12 
myotubes were infected with adenoviral GFP and PGC-1α, respectively, for 48 
hours. Sixteen hours before harvesting, the myotubes were treated with vehicle 
(PBS) or 10 ng/ml recombinant agrin. Subsequently, cells were fixed, incubated 
with rhodamine-labeled α-bungarotoxin and acetylcholine receptor clusters 
visualized by fluorescence microscopy. B, C, The average number of NMJ counted 
in 20 fields per genotype was normalized to the number of nuclei in these fields 
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and relative acetylcholine cluster numbers expressed as percentage of control 
mice. *p<0.05 between muscle fibers from MCK-PGC-1α and controls as well as 
fibers from MKO and controls, respectively. 
 
Fig. 3. PGC-1α and GABP activate NMJ gene promoters. A, C2C12 myoblasts 
were transfected with wild-type and N-box mutated promoter constructs, 
respectively, together with expression plasmids for PGC-1α, GABPA and GABPB1 
(the combination of GABPA and GABPB1 is referred to as GABP). The cells were 
subsequently differentiated for 2 days, harvested and luciferase activity measured. 
B, C2C12 myoblasts were transfected with NMJ promoter constructs together with 
expression plasmids for PGC-1α, GABP, PGC-1α 3A and GABPA as well as 
GABPB1 alleles (collectively called GABP P-mut) with mutated phosphorylation 
sites. The cells were subsequently differentiated for 2 days, harvested and 
luciferase activity measured. C, C2C12 myoblasts were transfected with NMJ 
promoter constructs together with expression plasmids for PGC-1α and GABP. 
The cells were subsequently differentiated for 2 days. Simultaneously, cells were 
treated with vehicle (PBS) 5 nM recombinant neuregulin-1 (NRG-1). Cells were 
harvested and luciferase activity measured. D, C2C12 myoblasts were transfected 
with NMJ promoter constructs together with expression plasmids for PGC-1α, 
GABP, PGC-1α 3A and GABPA as well as GABPB1 alleles (collectively called 
GABP P-mut) with mutated phosphorylation sites. The cells were subsequently 
differentiated for 2 days. Simultaneously, cells were treated with vehicle (PBS) 5 
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nM recombinant neuregulin-1 (NRG-1). Cells were harvested and luciferase activity 
measured. The bars depict average luciferase expression normalized to β-
galactosidase activity with the error bars representing standard deviations. 
 
Fig. 4. Physical interaction between PGC-1α and GABP requires 
phosphorylation and HCF. A, BOSC cells were transfected with expression 
plasmids for flag-tagged PGC-1α, myc-tagged GABPA and GABPB1, constitutively 
active MEKK (MEKK*) and HCF as indicated. Cells were harvested 48 hours after 
transfection, 1 mg of total protein from the cell lysates incubated with anti-myc 
beads and the bound proteins as well as input (10 μg protein) blotted with anti-flag 
and anti-myc antibodies. B, BOSC cells were transfected with expression plasmids 
for flag-tagged PGC-1α, myc-tagged GABPA and GABPB1, the phosphorylation-
deficient alleles flag-PGC-1α 3A, myc-GABPA P-mut and myc-GABPB1 P-mut, 
respectively, constitutively active MEKK (MEKK*) and HCF as indicated. Cells 
were harvested 48 hours after transfection, 1 mg of total protein from the cell 
lysates incubated with anti-myc beads and the bound proteins as well as input (10 
μg protein) blotted with anti-flag and anti-myc antibodies. C, C2C12 myotubes were 
transfected with expression plasmids for flag-tagged PGC-1α, myc-tagged GABPA 
and GABPB1, constitutively active MEKK (MEKK*) and HCF as indicated. The 
cells were differentiated for 2 days and simultaneously treated with 5 nM 
recombinant neuregulin-1 (NRG-1). Cells were harvested, 1 mg of total protein 
from the cell lysates incubated with anti-myc beads and the bound proteins as well 
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as input (10 μg protein) blotted with anti-flag and anti-myc antibodies. D, GABPA 
and GABPB1 bind as heterotetramers and upon phosphorylation of GABPB1, 
recruit phosphorylated PGC-1α and HCF. These phosphorylation events are 
induced by NRG-1 signaling or constitutive MAPK activation. 
 
Fig. 5. Specificity of NRG-1-induced NMJ gene expression via PGC-1α. A, B, 
Primary muscle cells were isolated from control and PGC-1α knockout animals. 
After differentiation into myotubes, cells were treated with vehicle (PBS) or 5 nM 
recombinant NRG-1 for 48 hours. RNA was isolated from harvested cells and 
relative gene expression levels of NMJ genes (panel A) and other PGC-1α target 
genes (panel B) determined by real-time PCR. *p<0.05 between vehicle and NRG-
1 treated cells. The bars depict average gene expression normalized to 18S rRNA 
levels with the error bars representing standard deviations. C, D, C2C12 myoblasts 
were transfected with a reporter plasmid containing the ERRα promoter and 
expression plasmids for PGC-1α, GABPA and GABPB1 (called GABP), ERRα and 
the phosphorylation-deficient PGC-1α 3A. The cells were subsequently 
differentiated for 2 days, harvested and luciferase activity controlled by PGC-1α 
and GABP (panel C) and PGC-1α and ERRα (panel D) measured. The bars depict 
average luciferase expression normalized to β-galactosidase activity with the error 
bars representing standard deviations. 
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Fig. 6. PGC-1α ameliorates muscle dystrophy in sedentary mdx mice. A, 5 
week old control, PGC-1α muscle-specific transgenic (MCK-PGC-1α), mdx and 
PGC-1α muscle-specific transgenic animals in the mdx background (MCK-PGC-
1α/mdx) were sacrificed and serum creatine kinase activity determined. The bars 
depict the average serum creatine kinase levels and error bars represent standard 
deviations. B, Haematoxilin and eosin (H&E) stained histology of gastrocnemius 
from control, PGC-1α muscle-specific transgenic (MCK-PGC-1α), mdx and PGC-
1α muscle-specific transgenic animals in the mdx background (MCK-PGC-1α/mdx). 
C, 5 week old control, PGC-1α muscle-specific transgenic (MCK-PGC-1α), mdx 
and PGC-1α muscle-specific transgenic animals in the mdx background (MCK-
PGC-1α/mdx) were injected i.p. with 1% v/w Evans blue solution and sacrificed 16 
hours later. Dye incorporation into muscle fibers was visualized by fluorescence 
microscopy. 
 
Fig. 7. PGC-1α improves muscle function in exercised mdx mice. A, 12 week 
old control, PGC-1α muscle-specific transgenic (MCK-PGC-1α), mdx and PGC-1α 
muscle-specific transgenic animals in the mdx background (MCK-PGC-1α/mdx) 
were run for one hour on a treadmill at a 15 degrees downhill angle (1st run). This 
exercise protocol was repeated after a resting period of 24 hours (2nd run). The 
bars depict average running times with the error bars representing standard 
deviations. B, Two hours after the 1st run, blood was drawn from the mice and 
serum creatine kinase activity determined. The bars depict average serum creatine 
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kinase levels with the error bars representing standard deviations. C, Mice were 
sacked after the second run and gastrocnemius sections stained with haematoxilin 
and eosin (H&E). D, Before sacking, Evans blue was injected i.p. and histological 
sections from diaphragms analyzed by fluorescence microscopy. 
 
Supplementary Fig. S1. Endogenous agrin is not controlled by PGC-1α in 
C2C12 myofibers. C2C12 myofibers were infected with adenoviral-encoded GFP 
or PGC-1α, respectively, and relative agrin mRNA levels determined by real-time 
PCR. The bars depict average gene expression normalized to 18S rRNA levels 
with the error bars representing standard deviations. 
 
Supplementary Fig. S2. Increase in AChR cluster number by PGC-1α. C2C12 
myotubes were infected with adenoviral-encoded GFP and PGC-1α, respectively, 
for 48 hours. Sixteen hours before harvesting, the myotubes were treated with 
vehicle (PBS) or 10 ng/ml recombinant agrin. Subsequently, cells were fixed, 
incubated with rhodamine-labeled α-bungarotoxin and acetylcholine receptor 
clusters visualized by fluorescence microscopy. Twenty different fields of vision 
were analyzed in terms of AChR cluster numbers and average numbers depicted 
in the bar graph with the error bars representing standard deviations. 
 
Supplementary Fig. S3. Differences in aneural AChR clusters in skeletal 
muscle fibers of PGC-1α transgenic and knockout animals. A, B, Single 
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muscle fibers from the different animal models were isolated and fixed. The fibers 
were double-stained with rhodamine-labeled α-bungarotoxin and DAPI. C, D, 
AChR clusters on fifty different single muscle fibers per genotype were counted 
and the number of muscle fibers with a specific number of AChR clusters depicted 
in the histograms. 
 
Supplementary Fig. S4. Reduced transcriptional activity of GABPA and 
GABPB1 phosphorylation mutants. C2C12 myoblasts were transfected with 
NMJ promoter constructs together with expression plasmids for PGC-1α, GABP, 
and GABPA as well as GABPB1 alleles with mutated phosphorylation sites 
(collectively called GABP P-mut). The cells were subsequently differentiated for 2 
days. Simultaneously, cells were treated with vehicle (PBS) 5 nM recombinant 
neuregulin-1 (NRG-1). Cells were harvested and luciferase activity measured. The 
bars depict average luciferase expression normalized to β-galactosidase activity 
with the error bars representing standard deviations. 
 
Supplementary Fig. S5. Reduction of PGC-1α-mediated endogenous NMJ 
gene induction by dominant negative GABP. C2C12 myoblasts were 
transfected with expression plasmids for GABP and dominant negative alleles of 
GABPA as well as GABPB1 (collectively called dnGABP), respectively. The cells 
were subsequently differentiated for 2 days and infected with adenoviral encoded 
PGC-1α. After 24 hours, mRNA was harvested and relative gene expression levels 
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measured by real-time PCR. The bars depict average gene expression normalized 
to 18S rRNA levels with the error bars representing standard deviations. *p<0.05 
between PGC-1α/GABP and PGC-1α/dnGABP-treated cells. 
 
Supplementary Fig. S6. Wild-type PGC-1α and PGC-1α 3A both coactivate 
nuclear respiratory factor 1. C2C12 myoblasts were transfected with a reporter 
plasmid containing a reporter construct with four repeats of an nuclear respiratory 
factor 1 (NRF-1) binding element and expression plasmids for NRF-1, PGC-1α and 
the phosphorylation-deficient PGC-1α 3A. The cells were subsequently 
differentiated for 2 days, harvested and luciferase activity measured. The bars 
depict average luciferase expression normalized to β-galactosidase activity with 
the error bars representing standard deviations. *p<0.05 between vector and NRF-
1 transfected cells. 
 
Supplementary Fig. S7. Reduction in muscle damage in MCK-PGC-1α/mdx 
animals. The proportion of muscle fibers with centrally located nuclei in sedentary 
(panel A) and post-exercise (panel C) animals was counted in twenty randomly 
chosen microscopic fields. The proportion of Evan’s blue positive muscle fibers in 
sedentary (panel B) and post-exercise (panel D) animals was counted in twenty 
randomly chosen fields. Bars depict average numbers and with the error bars 
representing standard deviations. *p<0.05 between mdx and MCK-PGC-1α/mdx 
animals. 
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Supplementary Fig. S8. Increased utrophin mRNA levels in MCK-PGC-1α/mdx 
vs. mdx animals. Relative utrophin expression levels were determined in skeletal 
muscle of mdx and MCK-PGC-1α/mdx animals by real-time PCR. The bars depict 
average gene expression normalized to 18S rRNA levels with the error bars 
representing standard deviations. *p<0.05 between mdx and MCK-PGC-1α/mdx 
animals. 
 
Supplementary Fig. S9. PGC-1α increases utrophin protein levels in vivo. 
Protein extracts from control and MCK-PGC-1α gastrocnemius were analyzed for 
utrophin protein expression in Western blots. 
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Utrophin expression
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